WI Harper Group| 2020-02-29
The following article comes from 动脉新医药 Author 徐文娟
Recently, WI Harper-backed Amwise Diagnostics,successfully completed the first close of its B round financing. This financing is led by Jiangsu Simcere Pharmaceutical Co., Ltd, a subsidiary of SimcereHoldings. The funds raised will mainly be used to promote the comprehensive upgrade of the Asian Breast Cancer Recurrence Risk Assessment and Detection Program — RecurIndex® in the Chinese market. Amwise Diagnostics previously raised its A round financing in 2016, supported by Alibaba Entrepreneurs Fund (AEF), WI Harper Group, Indonesia’s Lippo Group and other private equity funds.
Johnson Lin, Partner at WI Harper Group, said: “Precision medicine begins with precise diagnosis. We are very excited about Amwise Diagnostics’ progress in precision diagnostics, which has attracted such outstanding strategic partners and investors. In the coming year, Amwise Diagnostics will focus on bringing its RecurIndex® diagnostic products to more patients in need in China and the Asia Pacific region to address the chronic problem of overtreatment and undertreatment of breast cancer.”
Amwise Diagnostics is the leader in precision medicine technology for cancer in Asia. The chief scientist has been developing the core technique of RecurIndex® at Duke University and Koo Foundation Sun Yat-Sen Cancer Center since 2000. After 15 years of clinical tracking, genetic research and statistical analysis, they finally completed the only breast cancer recurrence risk assessment test developed based on Asian genetics, and provide solutions for accurate tumor detection in clinical use.
| Multigene testing will improve the precise treatment of breast cancer in Asia
The current treatment strategy for early-stage breast cancer is mainly surgery. In general, patients with early-stage breast cancer undergo surgical removal of the tumor followed by treatment with chemotherapy, radiation therapy, and targeted therapy are often used to reduce the risk of future recurrence according to different pathological types such as cancer stages and hormone receptors. As breast cancer diagnosis and treatment become increasingly precise, breast surgeons hope to accurately identify the patients who really need chemotherapy and radiotherapy, so as to reduce patients’ pain and improve the efficiency of diagnosis and treatment.
Breast cancer is the most common cancer in women worldwide, and meeting the growing needs of patients is the biggest challenge in this industry. With cancer genome sequencing as the basis of personalized medicine, the growth trend of the industry is obvious.
Not too long ago, Amwise Diagnostics was awarded the gold medal of the “2018 Hangzhou Overseas High-level Talent Innovation and Entrepreneurship Competition”, and was invited to settle in Xiaoshan as the base. Since then, the Company started to actively seek partnerships and formed strategic alliance with Simcere. By virtue of the core technology of RecurIndex®, the company has officially launched the product “28-Gene Panel for Breast Cancer Recurrence Risk Assessment and Detection”, and continued to recruit national as well as international talents to join the team. With Simcere taking the lead in forming the business mode of “Medicine + Diagnosis” (diagnosis and treatment integration) in China, the alliance will make joint progress to promote the development of China’s molecular diagnosis market.
Compared with current testing tools developed from European and American populations, the risk of distant metastasis is assessed only in patients with early luminal breast cancer. Based on Asian gene pool, RecurIndex® is the first to identify the high and low risk of distant metastasis and local recurrence, and to provide more comprehensive services for the majority of breast cancer patients by taking into account the patient’s age, tumor size and other clinical and pathological manifestations, and to assist doctors and patients to formulate appropriate plans for postoperative adjuvant chemotherapy and radiotherapy.
| Differentiated products meet the needs and provide assistance for the development of the industry
Simcere Breast Cancer Project team, the leading investor, believes that the understanding and management of breast cancer is largely based on Western research data. However, the epidemiology of breast cancer and the biological characteristics of tumors are different among different ethnic groups. In response to such clinical concerns, RecurIndex® has the potential to develop into a gene diagnosis and risk assessment service that are more suitable for Asian patients. With the industry advantages of Simcere and the standardized experience established by the “State Key Laboratory of Translational Medicine and Innovative Drug Development” of the Ministry of Science and Technology, Chinese breast cancer patients can use accurate, efficient, reliable and technologically advanced diagnostic products and services at home without going abroad.
Huang, Sea-lin, CEO of Amwise shared his excitement about the participation of investors in this round, in particular, to be a partner with an industry leader and pioneer likeSimcere. Investors’ recognition and investment are highly appreciated. The Amwise Diagnostics team will achieve a great leap forward in the marketing of RecurIndex® by 2020, and to improve the health and well-being of cancer patients.
Thanks to the rapid development of China’s biotechnology and medical industry, the tumor gene detection industry has high growth potential and is of high impact. With the accumulation of more real-world data and industry experience, the efficacy of treatments and the quality of life of patients will be improved in the near future and more cancer patients can benefit from it.
About Amwise Diagnostics
Amwise Diagnostics is a leader in precision medicine for cancer. Through the patented gene analysis technology, Amwise Diagnostics assists physicians and patients in determining the most appropriate personalized treatment strategy that has the optimal efficacy and minimal adverse events. Amwise Diagnostics was founded in 2015, with a presence in Singapore and Taipei, Taiwan. In 2018, among 700+ projects from more than 20 countries and regions, Amwise Diagnostics was awarded the gold award of “2018 Hangzhou Overseas High-level Talent Innovation and Entrepreneurship Competition” with its project of “Genetic Big Data of Tumor Recurrence Prediction”. Since then, Amwise Biomedical Technology (HangZhou) was founded in 2019 and established a base in Xiaoshan. It has been recruiting national and international talents to join the team. Amwise Diagnostics actively seeks scientific validation and clinical collaboration with top hospitals in China, and promotes accurate treatment of breast cancer and establishes multi-gene detection database for breast cancer among Chinese patients.
Simcere is a provider of precision medical solutions under Simcere Holdings, committed to creating accurate, comprehensive, fast and accessible diagnostic products and service systems in the major challenges to human health. By integrating a variety of leading molecular detection platforms and bioinformatics analysis capabilities, Simcere provides medical workers and medical institutions with the basis for precision medical decision-making in the treatment of tumor, CNS disorder, infectious diseases, pharmacogenomics, and autoimmune diseases. Moreover, Simcere also provides direct-to-consumer medical testing services to improve the quality, efficiency and experience of public healthcare through innovative service models.